Concourse Financial Group Securities, Inc. Editas Medicine, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.56 Billion
- Q2 2024
A detailed history of Concourse Financial Group Securities, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 75 shares of EDIT stock, worth $291. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75
Previous 75
-0.0%
Holding current value
$291
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding EDIT
# of Institutions
252Shares Held
58.7MCall Options Held
494KPut Options Held
417K-
Vanguard Group Inc Valley Forge, PA8.03MShares$31.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.78MShares$30.2 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$23.3 Million0.92% of portfolio
-
State Street Corp Boston, MA4.59MShares$17.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.46MShares$9.54 Million0.01% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $267M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...